Omega Completes Share Repurchase
TM Capital was retained by the Board of Directors of Omega Protein (NYSE) to act as financial advisor in connection with Omega’s $47.5 million share repurchase from Zapata Corporation (NYSE)
TM Capital was retained by the Board of Directors of Omega Protein (NYSE) to act as financial advisor in connection with Omega’s $47.5 million share repurchase from Zapata Corporation (NYSE)
TM Capital advised the Board of Directors of Immucor, Inc.(NASDAQ) in connection with a proxy contest in which all of Immucor’s directors were successfully re-elected
TM Capital acted as a financial advisor to the preferred equity holders of Smurfit-Stone in their successful legal challenge to the Company’s Plan of Reorganization to exit bankruptcy protection
TM Capital advised Armstrong Pharmaceuticals, Inc. (NASDAQ) in completing its $52 million stock swap merger with Medeva plc (LSE)
TM Capital provided Immucor, Inc. (NASDAQ) with an analysis of goodwill balances for potential impairment pursuant to FAS 142
TM Capital completed the sale of SteriGenics International, Inc. (NASDAQ) to Ion Beam Applications s.a. of Belgium for $214 million in cash
TM Capital advised the Special Committee of the Board of Directors of Industrial Defender, Inc. on the Company’s recapitalization from existing investors
TM Capital provided financial advisory services to CompuCredit Corporation (NASDAQ)
TM Capital acted as financial advisor to the independent members of the Board of Fibrek on its proposed Arrangement to amalgamate with Resolute Forest Products Inc.
TM Capital completed the $29 million sale of Medical Diagnostics, Inc. (NASDAQ) to Advanced NMR Systems Inc. (NASDAQ) following an unsolicited tender offer by Raytel Medical Corp. (NASDAQ)